This is an especially good strategy for semaglutide users who struggle with appetite and want to maximize nutrition in fewer eating opportunities
On the flipside, these groups are echo chambers, misinformation abounds, and it is difficult to fact check
GLP-1s in general are typically recommended and usually only covered by insurance for people with obesity (defined as a BMI greater than 30) as well as those with a BMI greater than 27 and one or more weight-related conditions such as high blood pressure, type 2 diabetes, or high cholesterol
Its mode of action includes: Inhibition of Pro-Inflammatory Pathways: KPV suppresses NF-B and MAPK signaling cascades, reducing cytokine production and inflammatory responses
This novel insight offers a fresh perspective on the mechanisms of tumor immune evasion and provides critical clues for the development of therapeutic strategies targeting the immune microenvironment [208]
Additional concerns, as reported by the FDA, include compounding multiple GLP1 receptor agonists together leading to serious side effects
